Radiation therapy

GE HealthCare closes MIM Software acquisition, bolstering its portfolio and advancing its precision care strategy

Retrieved on: 
Monday, April 1, 2024
Technology, Health, Other Health, Radiology, Oncology, Other Technology, Practice Management, Medical Devices, Software, Managed Care, General Health, Health Technology, Hardware, Data Management, Neurology, Automation, Diagnosis, Cardiology, Molecular imaging, American Urological Association, MRI, Prostate cancer, Nuclear medicine, SNMMI, Patient, PET, Radiation, Cancer, Society, Adjustment, Radiation therapy, Workflow, Radiopharmaceutical, GE HealthCare, SPECT, MIM, Brachytherapy, ASCO, European Association of Urology, Hand, Medical imaging

The availability of these offerings – including the MIM SurePlan and MIM Symphony families, MIM Maestro, MIM Encore, and more – is in alignment with GE HealthCare’s precision care strategy, which aims to deliver innovative digital solutions across care pathways for more precise, connected, and efficient care across disease states.

Key Points: 
  • The availability of these offerings – including the MIM SurePlan and MIM Symphony families, MIM Maestro, MIM Encore, and more – is in alignment with GE HealthCare’s precision care strategy, which aims to deliver innovative digital solutions across care pathways for more precise, connected, and efficient care across disease states.
  • "We are thrilled to welcome MIM Software, known for driving innovation in multimodal image analytics and workflow, to our global GE HealthCare team,” said Peter Arduini, President & CEO, GE HealthCare.
  • “These new capabilities align with our precision care strategy to personalize care, enhance hospital efficiency and clinician effectiveness, and appeal to new and existing GE HealthCare and MIM Software users who see this as an opportunity to better serve patients and help improve outcomes."
  • “Today marks an exciting new chapter for our team and technology,” adds Andy Nelson, CEO, MIM Software at GE HealthCare.

RefleXion and Limbus AI Announce Technology Integration to Expedite Cancer Treatment Planning

Retrieved on: 
Thursday, March 28, 2024
Software, Radiology, Biotechnology, Oncology, Health, Artificial Intelligence, Health Technology, Technology, Oar, Algorithm, Noise, Risk, Patient, Reflection, Radiation, Outline, Radiation therapy, Neoplasm, Limbus, Multimedia, FDA, Medical imaging

RefleXion Medical , Inc., a therapeutic oncology company, and Limbus AI , Inc., a provider of software solutions for cancer radiation therapy, today announced a licensing agreement to incorporate Limbus’ automated contouring software, Limbus Contour, into the RefleXion® X1 radiotherapy treatment planning system.

Key Points: 
  • RefleXion Medical , Inc., a therapeutic oncology company, and Limbus AI , Inc., a provider of software solutions for cancer radiation therapy, today announced a licensing agreement to incorporate Limbus’ automated contouring software, Limbus Contour, into the RefleXion® X1 radiotherapy treatment planning system.
  • View the full release here: https://www.businesswire.com/news/home/20240327446154/en/
    Unedited head-and-neck image generated by the RefleXion® X1 displays excellent contrast and detail resolution, and near-perfect Limbus AI contours visible on several structures.
  • (Photo: Business Wire)
    “Contouring is one of the most time-consuming tasks in radiotherapy planning, and often contributes to treatment delays,” said Sam Mazin, Ph.D., co-founder and chief technology officer at RefleXion.
  • Both treatment modalities, biologic and anatomic, will benefit from the efficiencies of Limbus Contour integration.

METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer

Retrieved on: 
Wednesday, March 27, 2024
Neurology, Radiology, Biotechnology, Pharmaceutical, Oncology, General Health, Health, Clinical Trials, EST, Baptist Health, METIS, Baptist Health South Florida, NSCLC, Webcast, Patient, Radiosurgery, Brain, Regulation, SRS, Disclosure, MD, Quality of life, Lung cancer, Congress, Regulation Fair Disclosure, Clinical trial, Cognition, Radiation therapy, Medical imaging

Patients treated with TTFields therapy and supportive care exhibited a median time to intracranial progression of 21.9 months compared to 11.3 months in patients treated with supportive care alone for brain metastasis (n=298; hazard ratio=0.67; P=0.016).

Key Points: 
  • Patients treated with TTFields therapy and supportive care exhibited a median time to intracranial progression of 21.9 months compared to 11.3 months in patients treated with supportive care alone for brain metastasis (n=298; hazard ratio=0.67; P=0.016).
  • Median TTFields therapy treatment duration was 16 weeks and median usage was 67%.
  • Consistent with previous studies, TTFields therapy was well-tolerated with sustained quality of life and neurocognitive function.
  • Certain secondary endpoints showed positive trends in favor of treatment with TTFields therapy, including time to distant progression and quality of life.

New Proton Therapy Treatment Centre named in Ben Stelter’s honour announced

Retrieved on: 
Thursday, March 14, 2024
Other Philanthropy, Oncology, Health, Children, Family, Philanthropy, Consumer, Foundation, Proton, University, Proton therapy, Intelligence, Physician, Patient, Neoplasm, Research, Travel, Cancer, MD, Surgeon, Ecosystem, Machine learning, Multimedia, Radiation therapy, Edmonton Oilers, Oiler, Medical imaging

Today, WestCan Proton Therapy Inc. announced their plans to invest in Canada’s first proton therapy treatment centre to be built in Edmonton.

Key Points: 
  • Today, WestCan Proton Therapy Inc. announced their plans to invest in Canada’s first proton therapy treatment centre to be built in Edmonton.
  • The centre will officially be named in honour of Ben Stelter, well-beloved six-year-old superfan and Edmonton Oilers team ambassador whose father, Mike, was a recipient of proton therapy.
  • Proton therapy, a highly precise form of radiation treatment, has long been sought after by Canadians seeking advanced cancer care.
  • On behalf of the EOCF, we would like to congratulate the Ben Stelter Foundation, Edmonton Global and WestCan Proton Therapy for bringing proton therapy treatment to Edmonton.

QT Imaging’s Breast Acoustic CT™ Scanner Used in Study for Early Identification of Response of Breast Cancer Patients to Neoadjuvant Chemotherapy

Retrieved on: 
Thursday, March 14, 2024
Research, Medical Devices, Women, Engineering, Manufacturing, Radiology, Consumer, Health, Science, Oncology, ACT, NAC, Partnership, Patient, Champaign–Urbana metropolitan area, Sunnybrook Health Sciences Centre, Biomarker, University of Illinois Urbana-Champaign, Cancer, University, Doctor of Philosophy, Electricity, MD, Computer engineering, Risk, Woman, Breast cancer, Safety, Radiation, Bangladesh Technical Education Board, Radiation therapy, Grainger College of Engineering, Medical imaging

This collaboration is part of a five-year research grant from National Institutes of Health/National Cancer Institute to develop an inexpensive, portable, safe, and repeatable imaging approach capable of accurate and early identification of response of breast cancer patients to neoadjuvant chemotherapy (NAC).

Key Points: 
  • This collaboration is part of a five-year research grant from National Institutes of Health/National Cancer Institute to develop an inexpensive, portable, safe, and repeatable imaging approach capable of accurate and early identification of response of breast cancer patients to neoadjuvant chemotherapy (NAC).
  • As part of this grant, Breast Acoustic CT™ (ACT) quantitative images with independent biomarkers known to be sensitive to cancer will be collected, and the response of cancer to therapy, will be derived from quantitative ultrasound based on backscatter analysis.
  • This collaboration also addresses the ongoing clinical need in breast cancer therapy for the development of an inexpensive, robust, and accurate technique to identify the response, within weeks, of breast cancer to neoadjuvant chemotherapy.
  • The early identification of non-responders to NAC or any cancer treatment remains a highly significant medical problem and necessary for adaptive precision medicine.

Naveris Announces New Data at EUROGIN International Multidisciplinary HPV Congress 2024

Retrieved on: 
Thursday, March 14, 2024
Research, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, ASCC, DART, Head, Disease, Associate, Patient, Oropharyngeal cancer, DNA, Anal cancer, University, Management, Cancer, MD, Pembrolizumab, HPV, SRL Diagnostics, OPC, Medicare, Recurrence, Radiation therapy, Huntsman Cancer Institute, Pharmaceutical industry

Naveris, Inc. , the leader in precision oncology diagnostics for viral-induced cancers, announced new data at EUROGIN International Multidisciplinary HPV Congress 2024 , taking place in Stockholm on March 13-16.

Key Points: 
  • Naveris, Inc. , the leader in precision oncology diagnostics for viral-induced cancers, announced new data at EUROGIN International Multidisciplinary HPV Congress 2024 , taking place in Stockholm on March 13-16.
  • The test provides a non-invasive and precise method for identifying HPV-driven cancers before there is clinical or radiographical evidence of disease.
  • Data supporting the clinical validity and utility of NavDx have been published in nearly 20 peer-reviewed publications, leading to recent positive Medicare and commercial insurance coverage policies.
  • The study involved 150 patients, with NavDx tested pre-treatment and every three months post-treatment and patients followed for five years.

The Inner Circle acknowledges Rumpa Amornmarn, MD as a Pinnacle Lifetime Member

Retrieved on: 
Tuesday, March 26, 2024
Adrian Dixon, Internal medicine, Organization, Private practice, Patient, Chulalongkorn University, Breast, Radiology, Cancer, MD, American College, Society, Johns Hopkins University, Multimedia, Radiation therapy, Parent, Inner circle, Medical device

KISSIMMEE, Fla., March 26, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Rumpa Amornmarn, MD is acknowledged as a Pinnacle Lifetime Member for her contributions to the Radiation Oncology industry.

Key Points: 
  • KISSIMMEE, Fla., March 26, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Rumpa Amornmarn, MD is acknowledged as a Pinnacle Lifetime Member for her contributions to the Radiation Oncology industry.
  • Dr. Amornmarn, a highly respected and board-certified specialist in cancer treatment, stands as a dedicated advocate for her patients' well-being.
  • Dr. Amornmarn specializes in the treatment of cancer patients, with a particular focus on breast and prostate cancers.
  • As the President of her private practice, she leads by example, supervising all medical staff, managing financial aspects, and ensuring optimal division performance.

Florida Selects DiaCarta's cfDNA Test (RadTox™) for Statewide Use to Detect Early Response of Cancer Treatment

Retrieved on: 
Monday, March 11, 2024
Plasma, Patient, DNA, Cancer, University, Medicine, Radiation therapy, Liquid biopsy, Medicare, University of Florida, Health, Medical imaging

Circulating cell-free DNA (cfDNA) concentration can serve as a valuable biomarker for monitoring tumor treatment response in cancer patients.

Key Points: 
  • Circulating cell-free DNA (cfDNA) concentration can serve as a valuable biomarker for monitoring tumor treatment response in cancer patients.
  • Throughout the course of treatment, changes in cfDNA concentration can be monitored to assess treatment response.
  • A decrease in cfDNA concentration over time may indicate a positive response to treatment, reflecting tumor shrinkage or reduced tumor burden.
  • By harnessing cell-free DNA (cfDNA) concentration as a biomarker, Dr. Okunieff aims to redefine the early detection of treatment response and resistance across a spectrum of cancer types.

American Urological Association Releases Salvage Therapy for Prostate Cancer Guideline

Retrieved on: 
Thursday, February 29, 2024
Therapy, Recurrence, Salvage therapy, Prostate cancer, Professor, ASTRO, Quality of life, Metastasis, Patient, Radiation, Risk, Society, University, AUA, SUO, Guideline, MPH, American Urological Association, Radiation therapy, Panel, Partnership, Medical imaging

BALTIMORE, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Today, the American Urological Association (AUA), in partnership with the American Society for Radiation Oncology (ASTRO) and the Society of Urologic Oncology (SUO), released the 2024 clinical practice guideline on salvage therapy for prostate cancer.

Key Points: 
  • BALTIMORE, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Today, the American Urological Association (AUA), in partnership with the American Society for Radiation Oncology (ASTRO) and the Society of Urologic Oncology (SUO), released the 2024 clinical practice guideline on salvage therapy for prostate cancer.
  • Understanding the evaluation and appropriate use of salvage therapies for patients with biochemical recurrence is a critical area of prostate cancer care.
  • “Thanks to the incredible expertise of the entire Panel, this guideline helps provide a roadmap that combines the latest advancements with thoughtful recommendations, empowering patients and clinicians alike.”
    This guideline has 30 recommendations and is a useful reference for effective evidence-based care related to salvage therapy for prostate cancer.
  • Salvage therapy for prostate cancer: AUA/ASTRO/SUO guideline part I: introduction and treatment decision-making at the time of suspected biochemical recurrence after radical prostatectomy.

Apollo Hospital in New Delhi Initiates First Non-Invasive ZAP-X Brain Tumor Treatment in South Asia

Retrieved on: 
Thursday, March 7, 2024
Technology, Medical Devices, Surgery, Hospitals, Health Technology, Other Health, Radiology, Robotics, Health, Oncology, Head, TK, Hospital, Neck, Neoplasm, Apollo, Multimedia, Pineal gland, Nausea, Vomiting, Stanford University, Apollo Hospitals, ZAP, Patient, Headache, Brain, Male, SRS, Radiation therapy, Stereotactic surgery, Partnership, Medical imaging

ZAP Surgical Systems, Inc., a leading innovator in the field of surgical robotics, today announced that Apollo Hospital in New Delhi, India, completed its first patient treatment using the new ZAP-X® Gyroscopic Radiosurgery® platform.

Key Points: 
  • ZAP Surgical Systems, Inc., a leading innovator in the field of surgical robotics, today announced that Apollo Hospital in New Delhi, India, completed its first patient treatment using the new ZAP-X® Gyroscopic Radiosurgery® platform.
  • This pioneering approach aims to maximally safeguard healthy brain tissue and preserve patient cognitive function.
  • “Pineal tumors are extremely difficult to remove with open surgery as they are anatomically located within the center of the brain.
  • “ZAP is honored to support Apollo Hospitals in expanding global access to this potentially life-saving treatment.”